Metabolic profiling of samples from PCa patients is of great interest because it may lead to the detection and identification of statistical significant biomarkers related to prostate cancer and subsequently solve the problem of low specificity and sensitivity of the current PCa screening, diagnosis, staging, and monitoring protocols based on measurements of the serum prostate-specific antigen (PSA) or its derivatives, digital rectal examination (DRE), histopathological studies of core needle biopsies, and Gleason Scores [6,7,8,9,10,11]. The gene discussed is KLK3; the disease is Familial prostate cancer.